Company

Management

  • Maria Palasis, Ph.D.

    President and Chief Executive Officer

    Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO, and previously CTO, of 480 Biomedical and Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

    Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO, and previously CTO, of 480 Biomedical and Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

  • Don Elsey

    Chief Financial Officer

    Don Elsey has 30 years of experience in financial management, SEC reporting and operations, including roles as Chief Financial Officer of four biotechnology companies at various stages of growth and development. He most recently was Chief Financial Officer of Senseonics, Inc., where he played a key role in its public offering and leading the company to establish commercial-stage capabilities for continuous glucose monitoring products. Previously, he served as Chief Financial Officer of Regado Biosciences Corporation and of LifeCell Corporation. Mr. Elsey was Chief Financial Officer of Emergent Biosolutions Corporation where he led its initial public offering and transformed its financial operations to support its expansion into new markets and global locations. Earlier in his career, he held senior financial positions at BioVeris Corporation, Igen, Inc. and PE Corporation (Applera). Mr. Elsey currently serves on the boards of directors of OpGen, Inc. and RegeneRx Biopharmaceuticals, Inc. He holds a B.A. in economics and an M.B.A. in finance from Michigan State University, and he is also a certified management accountant.

    Don Elsey has 30 years of experience in financial management, SEC reporting and operations, including roles as Chief Financial Officer of four biotechnology companies at various stages of growth and development. He most recently was Chief Financial Officer of Senseonics, Inc., where he played a key role in its public offering and leading the company to establish commercial-stage capabilities for continuous glucose monitoring products. Previously, he served as Chief Financial Officer of Regado Biosciences Corporation and of LifeCell Corporation. Mr. Elsey was Chief Financial Officer of Emergent Biosolutions Corporation where he led its initial public offering and transformed its financial operations to support its expansion into new markets and global locations. Earlier in his career, he held senior financial positions at BioVeris Corporation, Igen, Inc. and PE Corporation (Applera). Mr. Elsey currently serves on the boards of directors of OpGen, Inc. and RegeneRx Biopharmaceuticals, Inc. He holds a B.A. in economics and an M.B.A. in finance from Michigan State University, and he is also a certified management accountant.

  • Corinne Noyes

    Senior Vice President of Commercial Strategy & Market Development

    Corinne Noyes has more than 20 years of commercial experience working with pharmaceutical companies from seed-stage ventures to multi-national corporations. An expert at maximizing the commercial potential of therapeutic assets, she brings to the company extensive experience across varied technologies and therapeutic areas. Prior to Lyra she built a thriving consultancy, where she advised leading start-up biotech companies and contributed to successful M&A activity exceeding over $2.5B in deal value and developed commercial strategies that collectively raised over $300M in IPOs. Previously, Corinne held commercial leadership positions at Biogen in global new product planning and marketing. She began her life sciences career in the New York pharmaceutical practice of Deloitte Management Consulting. Corinne holds a B.A. and B.B.A. from St. Mary’s College of Notre Dame and an M.B.A. from the University of Chicago.

    Corinne Noyes has more than 20 years of commercial experience working with pharmaceutical companies from seed-stage ventures to multi-national corporations. An expert at maximizing the commercial potential of therapeutic assets, she brings to the company extensive experience across varied technologies and therapeutic areas. Prior to Lyra she built a thriving consultancy, where she advised leading start-up biotech companies and contributed to successful M&A activity exceeding over $2.5B in deal value and developed commercial strategies that collectively raised over $300M in IPOs. Previously, Corinne held commercial leadership positions at Biogen in global new product planning and marketing. She began her life sciences career in the New York pharmaceutical practice of Deloitte Management Consulting. Corinne holds a B.A. and B.B.A. from St. Mary’s College of Notre Dame and an M.B.A. from the University of Chicago.

  • Laura Edgerly-Pflug

    Senior Vice President of Technical Operations

    Laura Edgerly-Pflug brings over 25 years of experience in the biotechnology and pharmaceutical industry, specifically focused on manufacturing and quality control. She has extensive experience in product and process development, scale-up from bench to commercial process, all areas of good manufacturing process compliance, and the development and implementation of quality management systems. Previously, Laura was Vice President of Technical Operations at Adgero Biopharmaceuticals where she led the manufacturing, formulation, analytical, and quality control/quality assurance activities for a therapeutic to treat cutaneous cancers. She worked at Insmed as a Vice President of Technical Operations and Chemistry, Manufacturing and Controls, with responsibilities for product development, global CMC documentation and submissions, and manufacturing of sterile liposomal products from preclinical development through commercialization. Laura held leadership positions at Ovation Pharmaceuticals, Biomira, and The Liposome Company.  She holds a B.S. in Chemistry from Kean College of New Jersey, attended Rutgers College of Pharmacy, and has authored pharmaceutical patents and publications.

    Laura Edgerly-Pflug brings over 25 years of experience in the biotechnology and pharmaceutical industry, specifically focused on manufacturing and quality control. She has extensive experience in product and process development, scale-up from bench to commercial process, all areas of good manufacturing process compliance, and the development and implementation of quality management systems. Previously, Laura was Vice President of Technical Operations at Adgero Biopharmaceuticals where she led the manufacturing, formulation, analytical, and quality control/quality assurance activities for a therapeutic to treat cutaneous cancers. She worked at Insmed as a Vice President of Technical Operations and Chemistry, Manufacturing and Controls, with responsibilities for product development, global CMC documentation and submissions, and manufacturing of sterile liposomal products from preclinical development through commercialization. Laura held leadership positions at Ovation Pharmaceuticals, Biomira, and The Liposome Company.  She holds a B.S. in Chemistry from Kean College of New Jersey, attended Rutgers College of Pharmacy, and has authored pharmaceutical patents and publications.

  • Robert Solomon

    Vice President of Finance

    Robert Solomon has a 20-year track record of guiding entrepreneurial life sciences companies through the financial and accounting complexities unique to the industry. Prior to Lyra Therapeutics, he was Vice President of Finance for GI Dynamics, Inc. In this role, Robert was responsible for accounting, SEC and Australian Stock Exchange reporting, financial planning, tax compliance, risk management and treasury. Previously, Robert held senior finance roles at Ironwood Pharmaceuticals, Targanta Therapeutics, Therion Biologics and Aspect Medical Systems. Robert holds an M.B.A. from the Stern School of Business at New York University and a B.S. from Cornell University.

    Robert Solomon has a 20-year track record of guiding entrepreneurial life sciences companies through the financial and accounting complexities unique to the industry. Prior to Lyra Therapeutics, he was Vice President of Finance for GI Dynamics, Inc. In this role, Robert was responsible for accounting, SEC and Australian Stock Exchange reporting, financial planning, tax compliance, risk management and treasury. Previously, Robert held senior finance roles at Ironwood Pharmaceuticals, Targanta Therapeutics, Therion Biologics and Aspect Medical Systems. Robert holds an M.B.A. from the Stern School of Business at New York University and a B.S. from Cornell University.

  • Danny Concagh

    Senior Director, Research and Development

    Danny Concagh has extensive expertise in polymer science and formulation that he has cultivated over 20 years in the pharmaceutical and biotech industries. In his role at Lyra Therapeutics, he led the design of Lyra’s transmucosal therapeutic matrix and oversees Lyra’s pilot manufacturing facility. Prior to Lyra, he held positions at Copley Pharmaceuticals, GelTex Pharmaceuticals and Genzyme. At GelTex Pharmaceuticals (acquired by Genzyme in 2000 for $1.1 billion), he was instrumental in the discovery and development of several oral non-systemic polymeric drugs. Danny is an inventor on numerous issued or pending patents and holds an M.Sc. in Organic Chemistry from the National University of Ireland, Galway.

    Danny Concagh has extensive expertise in polymer science and formulation that he has cultivated over 20 years in the pharmaceutical and biotech industries. In his role at Lyra Therapeutics, he led the design of Lyra’s transmucosal therapeutic matrix and oversees Lyra’s pilot manufacturing facility. Prior to Lyra, he held positions at Copley Pharmaceuticals, GelTex Pharmaceuticals and Genzyme. At GelTex Pharmaceuticals (acquired by Genzyme in 2000 for $1.1 billion), he was instrumental in the discovery and development of several oral non-systemic polymeric drugs. Danny is an inventor on numerous issued or pending patents and holds an M.Sc. in Organic Chemistry from the National University of Ireland, Galway.